Cannabidiol and Depression: Promise and Challenge in Building an Evidence Base

IF 0.4 Q4 PEDIATRICS

Adolescent Psychiatry Pub Date : 2023-10-04 DOI:10.2174/0122106766234102230919064455

Amelia D. Moser, Melissa M. Batt, L Cinnamon Bidwell, Roselinde H. Kaiser

{"title":"Cannabidiol and Depression: Promise and Challenge in Building an Evidence Base","authors":"Amelia D. Moser, Melissa M. Batt, L Cinnamon Bidwell, Roselinde H. Kaiser","doi":"10.2174/0122106766234102230919064455","DOIUrl":null,"url":null,"abstract":"Background: Interest in the potential mental health effects of cannabidiol (CBD) has increased recently, with a surge in commercial and pharmaceutical development of CBD products and a concomitant rise in consumer use. However, despite the widespread and growing use of CBD products by adults and adolescents, the mental health effects of CBD remain largely unknown. Objective: The goals of this review are: 1) to briefly review the evidence base for the mental health effects of CBD, using depression as an exemplar, and 2) to systematically outline complementary study designs needed to test CBD effects, together with challenges and special considerations related to each design. Methods: This review integrates empirical findings related to CBD's effects on mental health outcomes with the literature on intervention trial design and current legal regulations pertaining to CBD. Conclusion: Complementary controlled and observational studies of CBD are necessary to substantiate claims of mental health benefits, including for clinical depression and in pediatric populations. Investigators must consider challenges and opportunities specific to CBD as an intervention, including legal regulations, commercial or pharmaceutical product choice, dosing and bioavailability, and safety.","PeriodicalId":43326,"journal":{"name":"Adolescent Psychiatry","volume":"4 1","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Adolescent Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122106766234102230919064455","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Interest in the potential mental health effects of cannabidiol (CBD) has increased recently, with a surge in commercial and pharmaceutical development of CBD products and a concomitant rise in consumer use. However, despite the widespread and growing use of CBD products by adults and adolescents, the mental health effects of CBD remain largely unknown. Objective: The goals of this review are: 1) to briefly review the evidence base for the mental health effects of CBD, using depression as an exemplar, and 2) to systematically outline complementary study designs needed to test CBD effects, together with challenges and special considerations related to each design. Methods: This review integrates empirical findings related to CBD's effects on mental health outcomes with the literature on intervention trial design and current legal regulations pertaining to CBD. Conclusion: Complementary controlled and observational studies of CBD are necessary to substantiate claims of mental health benefits, including for clinical depression and in pediatric populations. Investigators must consider challenges and opportunities specific to CBD as an intervention, including legal regulations, commercial or pharmaceutical product choice, dosing and bioavailability, and safety.

查看原文本刊更多论文

大麻二酚和抑郁症:建立证据基础的希望和挑战

背景:最近，随着CBD产品的商业和制药开发的激增以及消费者使用的增加，人们对大麻二酚(CBD)潜在的心理健康影响的兴趣有所增加。然而，尽管成人和青少年对CBD产品的使用越来越广泛，而且越来越多，但CBD对心理健康的影响在很大程度上仍然未知。目的:本综述的目的是:1)简要回顾CBD对心理健康影响的证据基础，以抑郁症为例;2)系统地概述测试CBD效应所需的补充研究设计，以及与每种设计相关的挑战和特殊考虑。方法:本综述将CBD对心理健康结果影响的实证研究结果与干预试验设计和现行CBD法律法规相关的文献相结合。结论:有必要进行补充性的对照和观察性研究，以证实CBD对心理健康的益处，包括对临床抑郁症和儿科人群的益处。调查人员必须考虑到CBD作为干预措施所特有的挑战和机遇，包括法律法规、商业或制药产品的选择、剂量和生物利用度以及安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Adolescent Psychiatry PEDIATRICS-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Adolescent Psychiatry a peer-reviewed journal, aims to provide mental health professionals who work with adolescents with current information relevant to the diagnosis and treatment of psychiatric disorders in adolescents. Adolescent Psychiatry reports of original research, critical reviews of topics relevant to practitioners, clinical observations with analysis and discussion, analysis of philosophical, ethical or social aspects of the fields of psychiatry and mental health, case reports with discussions, letters, and position papers. Topics include adolescent development and developmental psychopathology, psychotherapy and other psychosocial treatment approaches, psychopharmacology, and service settings and programs. The primary focus of the work should be on adolescents, transition-aged youth, The primary focus of the work should be on adolescents, transition-aged youth, or emerging adults, that is, persons 12-24 years of age . Articles on families of adolescents, or adults who have been followed since adolescence will also be considered.